SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
- Mechanism
- Curator reviewed
SSR126517E is a biotinylated form of idraparinux. It can be neutralized with intravenous recombinant avidin. Avidin binds biotinylated fondaparinux with high affinity, and the complex is then rapidly cleared.
SSR126517E also has an advantage over idraparinux in that an antidote is available when rapid reversal is required. None of the new agents has a specific antidote except SSR126517E. The lack of an antidote in other anticoagulants agents has been a major cause for the development of SSR126517E.
- Primary indication
- Investigated for use/treatment in thrombosis and venous thromboembolism.Curator reviewed
- Code names
- SSR-126517E
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with SSR-126517E, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account